Hopper Parent Inc. acquires Hologic, Inc. (2025)

Deal facts

Buyer: Hopper Parent Inc.
Target: Hologic, Inc.
Deal value: Not disclosed
Announced: 21 October 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

7 Apr 2026CompletedClosed
Hopper Parent Inc. completes acquisition of Hologic, Inc.
Introductory Note This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Merger (as defined below) pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the “ Merger Agreement ”), by and among Hologic, Inc., a Delaware corporation (the “ Company ”), Hopper Parent Inc., a Delaware corporation (“ Parent ”), and Hopper Merger
Source

OpinionExit Mode editorial

We see a striking anomaly in the data provided for this archive entry. The record states that Hopper Parent Inc. has completed the acquisition of Hologic, Inc. on 21 October 2025, yet it lists the deal value and currency as null. In the healthcare sector, where asset valuations are typically driven by rigorous clinical data and regulatory approval pathways, a completed transaction without a disclosed price is highly irregular. This omission obscures the true scale of the going-private move and leaves the SME founder reader without a clear benchmark for what a successful exit in this space currently commands.

The consideration structure offers the only concrete clue regarding the deal mechanics. The use of cash alongside an earn-out suggests the buyer is managing risk by tying a portion of the final payment to future performance milestones. This is a common tactic when a buyer wants to secure a target but remains uncertain about the long-term integration of its revenue streams or the stability of its regulatory standing. In the US healthcare landscape, such arrangements often reflect the buyer's desire to mitigate exposure to potential CMA-style competition reviews or FCA prospectus complexities that might arise post-close. It shifts the burden of proof onto the target management team to deliver results after the deal has technically closed.

This structure fundamentally changes the nature of the exit for the original owners. A clean cash exit provides immediate liquidity and a definitive end to the journey. An earn-out, however, extends the commitment period and keeps the founders or management team on the hook for a longer duration. The lack of a headline figure in the public record further complicates the ability to assess whether the initial offer was fair or if the final payout will be diluted by the contingencies attached to the earn-out component.

Our view is that the absence of a fixed total value in the announcement signals a high degree of uncertainty regarding the final economic outcome. For the SME founder reading this, the immediate lesson is clear. Before signing any term sheet that includes an earn-out, you must demand a written schedule detailing the exact metrics, timelines, and caps that will determine the deferred payment. Do not rely on verbal assurances or vague performance targets, as these clauses are often the primary source of post-deal disputes and can significantly reduce your actual return.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from Hopper Parent Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history